<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899415</url>
  </required_header>
  <id_info>
    <org_study_id>LTCR-HCC-3-1</org_study_id>
    <nct_id>NCT03899415</nct_id>
  </id_info>
  <brief_title>TCR-Redirected T Cells Therapy in Patient With HBV Related HCC</brief_title>
  <official_title>TCR-Redirected T Cells Therapy in Patient With HBV Related HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lion TCR Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center. single arm, open-label study to determine the safety and clinical
      benefit of TCR-redirected T cell therapy in patient with HBV related HCC post hepatectomy or
      radiofrequency ablation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation based in Incidences of adverse events/serious adverse events</measure>
    <time_frame>Up to 1 month after the last infusion</time_frame>
    <description>Review the safety profile of T-Cell Therapy by assessing adverse/serious adverse events reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Start of Treatment until first documented CR or PR, assessed up to 56 treatment weeks (protocol-defined treatment duration is until disease progression, death, or loss to follow up, whichever came first)</time_frame>
    <description>Tumour assessment will be according to mRECIST v1.1. This is based on percentage of participants with Complete Response (CR) and Partial Response (PR) according to mRECIST v1.1 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>Up to 5 years from the last infusion</time_frame>
    <description>Overall Survival (OS) defined as the time from randomisation until death by any cause. Participants will be followed up for survival follow up for at least five years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TCR-Redirected T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV antigen specific TCR redirected T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TCR redirected T cells</intervention_name>
    <description>HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10^4 - 5x10^6 TCR redirected T cells by IV infusion.</description>
    <arm_group_label>TCR-Redirected T Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Expression of the specific human leukocyte antigen (HLA) class I profile

          2. Hepatocellular carcinoma (HCC) with positive test for hepatitis B virus surface
             antigen (HBsAg)

          3. BCLC stage C

          4. At least 1 month after surgical intervention or 2 weeks after TACE (may include other
             type of resection/ablation) No major post-operative complication

          5. Laboratory criteria:

               1. Liver function: Child A, ALT &lt; 200 U/L, AST &lt; 200 U/L, Tbil &lt; 17.1umol/L

               2. Renal Function: Creatinine clearance ≥ 60ml/minute

               3. Cardiac Function: No abnormality in cardiac enzyme and ECG

               4. Pulmonary Function (Lung): No abnormality in chest X-ray

          6. Sexually active subjects must be willing to use an acceptable method of contraception

          7. Willing and able to provide written, signed informed consent after the nature of the
             study has been explained, and prior to any research-related procedures

        Exclusion Criteria:

          1. Subject experiencing acute infection or gastric bleeding within 30 days

          2. Mid to late stage cirrhosis, i.e. Child-Pugh Score ≥ 7

          3. Known history of testing positive for human immunodeficiency virus (HIV)

          4. Other liver complications, including alcoholic liver disease, non-alcoholic autoimmune
             liver disease, drug induced liver disease

          5. Serious systemic conditions, such as mental illness, cerebrovascular disease, coronary
             heart disease, diabetes, epilepsy

          6. Women who are pregnant or breast-feeding

          7. History of allergic reaction to blood products or investigational products

          8. History of chronic alcoholism or drug abuse/addiction

          9. Require systemic medications, such as steroids during the period of study drug
             administration

         10. Exposure to any cell therapy such as, but not limited to NK, CIK, DC, CTL, stem cells
             therapy 6 months prior to study drug administration

         11. Use of any investigational product (IP) or investigational medical device

         12. Any condition which could jeopardize the safety of the patient and his/her compliance
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fusheng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing 302 Hospital of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi</last_name>
    <phone>86-10-63879735</phone>
    <email>shiming302@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing 302 Hospital of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fusheng Wang, MD</last_name>
      <phone>01066933328</phone>
      <email>fswang302@163.com</email>
    </contact>
    <investigator>
      <last_name>Fusheng Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

